Study of of URC102 to Assess the Efficacy and Safety in Gout Patients
Status:
Completed
Trial end date:
2020-11-29
Target enrollment:
Participant gender:
Summary
To confirm the safety and efficacy (dose response and optimal dose according to the serum
uric acid response rate) of URC102 when orally-administered to patients with gout and
gout-related hyperuricemia in comparison with placebo.
Therapeutic dose-finding study, Placebo-controlled, randomized, double-blind, multicenter,
phase 2 clinical trial.